<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="63519">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02278991</url>
  </required_header>
  <id_info>
    <org_study_id>CL0022-01</org_study_id>
    <nct_id>NCT02278991</nct_id>
  </id_info>
  <brief_title>Bard LifeStent and Lutonix DCB for Treatment of Long Lesions in Femoropopliteal Arteries</brief_title>
  <official_title>A Prospective, Multicenter, Single-Arm, Post-Market Study Using the Lutonix Drug Coated Balloon for Post-Dilatation of the Bard LifeStent Vascular Stent for Treatment of Long Lesions in Femoropopliteal Arteries</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>C. R. Bard</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>C. R. Bard</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objective of this study is to evaluate the safety and efficacy of Lutonix 035 Drug Coated
      Dilatation PTA Catheter with Bard LifeStent Vascular Stent (hereinafter referred to as
      LifeStent) for treatment of long (10-24 cm) lesions in the SFA.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>October 2014</start_date>
  <completion_date type="Anticipated">November 2018</completion_date>
  <primary_completion_date type="Anticipated">September 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The primary efficacy endpoint is primary patency at 12 months. Primary patency is defined as the absence of target lesion restenosis and freedom from target lesion revascularization.</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The primary safety endpoint is freedom from the composite endpoint of death, index limb amputation, and target vessel revascularization at 30 days.</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Procedural success, defined as attainment of ≤30% residual stenosis by quantitative angiography (QA) immediately after intervention in the absence of peri-procedural complications.</measure>
    <time_frame>Immediately after Intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Technical success, defined as attainment of ≤30% residual stenosis by QA.</measure>
    <time_frame>Immediately after intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Device success, defined as successful delivery of device to target lesion and performance when used according to the clinical investigational plan.</measure>
    <time_frame>Immediately after intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom from TLR after 30 days, and 6, 12 and 24 months post-index procedure.</measure>
    <time_frame>30 days, 6, 12 and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom from TVR after 30 days, and 6, 12 and 24 months post-index procedure.</measure>
    <time_frame>30 days, 6, 12 and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in resting ankle brachial index (ABI) from baseline to 30 days, and 6, 12 and 24 months post-index procedure</measure>
    <time_frame>30 days, 6, 12 and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Rutherford Classification from baseline to 30 days, and 6, 12 and 24 months post-index procedure</measure>
    <time_frame>30 days, 6, 12 and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause death</measure>
    <time_frame>30 days, 6, 12 and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amputation (above the ankle)-free survival</measure>
    <time_frame>30 days, 6, 12 and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target limb reintervention for treatment of thrombosis of target vessel or embolization to its distal vasculature</measure>
    <time_frame>30 days, 6, 12 and 24 months</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">149</enrollment>
  <condition>Peripheral Artery Disease</condition>
  <arm_group>
    <arm_group_label>Lutonix Drug Coated Balloon</arm_group_label>
    <description>Paclitaxel coated balloon catheter</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Lutonix Drug Coated Balloon</intervention_name>
    <description>Subject will receive treatment with the Lutonix Drug Coated Balloon</description>
    <arm_group_label>Lutonix Drug Coated Balloon</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Hospital Patients
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age ≥18 years

          2. The subject is legally competent and able to understand the information on the study,
             has been informed of the nature, the scope and the relevance of the study,
             voluntarily agrees to participation and the study's provisions, and has duly signed
             the Informed Consent Form (ICF)

          3. Rutherford Category 2-4

          4. Target de novo lesion(s) or non-stented restenotic lesion(s) has angiographic
             evidence of ≥50% stenosis or occlusion (by visual estimate) and is amenable to
             treatment with LifeStent and Lutonix DCB

          5. Patients must be able to be treated with Lutonix DCB and LifeStent

          6. Total treated segment(s) of 10-24 cm in length

          7. Target vessel reference diameter is 4.0-7.0 mm (by visual estimate) and able to be
             treated with available device size matrix

          8. At least one patent native outflow artery to the ankle free from significant lesion
             (≥50% stenosis) as confirmed by angiography (treatment of outflow disease is NOT
             permitted; treatment of in-flow disease is permitted prior to treatment with
             LifeStent)

        Exclusion Criteria:

          1. Life expectancy of &lt;1 year

          2. Inability to take required antiplatelet/anticoagulant medications per the LifeStent
             and Lutonix DCB IFU, or known contraindication (including allergic reaction) or
             sensitivity to contrast media, nickel, titanium or tantalum that cannot be adequately
             managed with pre- and post-procedure medication

          3. Intended treatment of outflow disease during the index procedure

          4. Intended use of laser, atherectomy or cryoplasty during index procedure

          5. Sudden symptom onset, acute vessel occlusion, or acute or subacute thrombus in target
             vessel

          6. History of stroke within 3 months

          7. History of myocardial infarction, thrombolysis or angina within 2 weeks of enrollment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Zeller, Prof.</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <location>
    <facility>
      <name>Klinikum Arnsberg</name>
      <address>
        <city>Arnsberg</city>
        <zip>59755</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herz- und Gefäßzentrum Bad Bevensen</name>
      <address>
        <city>Bad Bevensen</city>
        <zip>29549</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitäts-Herzzentrum Freiburg Bad Krozingen</name>
      <address>
        <city>Bad Krozingen</city>
        <zip>79189</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Angiologikum Hamburg</name>
      <address>
        <city>Hamburg</city>
        <zip>22527</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik Immenstadt</name>
      <address>
        <city>Immenstadt</city>
        <zip>87509</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Kassel</name>
      <address>
        <city>Kassel</city>
        <zip>34125</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UKSH - Campus Lübeck</name>
      <address>
        <city>Lübeck</city>
        <zip>23538</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RoMed Klinikum Rosenheim</name>
      <address>
        <city>Rosenheim</city>
        <zip>83022</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gefäßzentrum Sonneberg</name>
      <address>
        <city>Sonneberg</city>
        <zip>96515</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Weiden</name>
      <address>
        <city>Weiden</city>
        <zip>92637</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University General Hospital of Patras</name>
      <address>
        <city>Patras</city>
        <zip>26504</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPZOZ Sanok</name>
      <address>
        <city>Sanok</city>
        <zip>38-500</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Greece</country>
    <country>Poland</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <lastchanged_date>September 26, 2016</lastchanged_date>
  <firstreceived_date>October 28, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Peripheral Arterial Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
